Inventor · disambiguated record
Patrick Lacombe
Also filed as: LACOMBE PATRICK
15 granted patents·9 pending applications·110 citations·filing 1999–2014
91Inventor score
Files withMERCK FROSST CANADA INC6MERCK FROSST CANADA LTD4DUBE DANIEL3BAYLY CHRISTOPHER I2CHEN AUSTIN CHIH-YU2
Top patents by PatentIndex Score
24 records- 0192US6410563B1Substituted 8-arylquinoline phosphodiesterase-4 inhibitorsMERCK FROSST CANADA INC·Filed 2000·Granted Jun 25, 2002·42 cites·23 claims
- 0288US7622501B2Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitorsMERCK FROSST CANADA INC·Filed 2005·Granted Nov 24, 2009·14 cites·15 claims
- 0380US6369084B1Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatmentMERCK FROSST CANADA INC·Filed 2000·Granted Apr 9, 2002·15 cites·21 claims
- 0478US6369082B1Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatmentMERCK FROSST CANADA INC·Filed 2000·Granted Apr 9, 2002·12 cites·23 claims
- 0572US7153968B28-(biaryl)quinoline PDE4 inhibitorsMERCK FROSST CANADA LTD·Filed 2003·Granted Dec 26, 2006·7 cites·23 claims
- 0670US6919353B2Substituted 8-arylquinolune PDE4 inhibitorsMERCK FROSST CANADA INC·Filed 2002·Granted Jul 19, 2005·5 cites·23 claims
- 0769US8063105B2Renin inhibitorsBAYLY CHRISTOPHER I·Filed 2006·Granted Nov 22, 2011·1 cites·8 claims
- 0869US6627656B2Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful thereforeFiled 2001·Granted Sep 30, 2003·5 cites·5 claims
- 0966US7482456B28-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitorsMERCK FROSST CANADA·Filed 2004·Granted Jan 27, 2009·3 cites·25 claims
- 1063US7144896B2Hetero-bridge substituted 8-arylquinoline pde4 inhibitorsMERCK FROSST CANADA LTD·Filed 2003·Granted Dec 5, 2006·2 cites·27 claims
- 1152US7238706B24-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitorsMERCK FROSST CANADA LTD·Filed 2004·Granted Jul 3, 2007·0 cites·15 claims
- 1249US2011237622A1Renin inhibitorsMERCK FROSST CANADA LTD·Filed 2009·Application pending·0 cites
- 1348US2008070940A14-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing sameDUBE DANIEL·Filed 2007·Application pending·0 cites
- 1446US2007099951A14-oxo-1-(3-substituted phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing sameDUBE DANIEL·Filed 2006·Application pending·0 cites
- 1545US7342024B24-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitorsMERCK FROST CANADA LTD·Filed 2003·Granted Mar 11, 2008·0 cites·12 claims
- 1645US2006040981A1Use of phosphodiesterase-4 inhibitors as enhancers of cognitionDUBE DANIEL·Filed 2003·Application pending·0 cites
- 1744US2012046293A1Renin inhibitorsBAYLY CHRISTOPHER I·Filed 2011·Application pending·0 cites
- 1842US8334308B2Renin inhibitorsJUTEAU HELENE·Filed 2008·Granted Dec 18, 2012·0 cites·11 claims
- 1941US8889714B23,4-substituted piperidine derivatives as renin inhibitorsCHEN AUSTIN CHIH-YU·Filed 2009·Granted Nov 18, 2014·0 cites·15 claims
- 2041US6277839B1Biphenylene lactams as prostaglandin receptor ligandsMERCK FROSST CANADA INC·Filed 1999·Granted Aug 21, 2001·4 cites·7 claims
- 2141US2011152316A13,4-substituted piperidine derivatives as renin inhibitorsCHEN AUSTIN CHIH-YU·Filed 2009·Application pending·0 cites
- 2240US2008242722A1Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular EventsDUFRESNE CLAUDE·Filed 2005·Application pending·0 cites
- 2338US2016031935A1Small molecule modulators of pcsk9 and methods of use thereofADAERATA LTD PARTNERSHIP·Filed 2014·Application pending·0 cites
- 2430US2012035214A1Renin inhibitorsMCKAY DANIEL J·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Patrick Lacombe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →